Taiwan
all page content
all page content
Main body page content
LATEST ARTICLES
-
DBS’s purchase of Citi’s local consumer business in January was a timely reminder of Taiwan’s allure. Yes, the island lies on a geopolitical fault line and the banking sector is crowded. But it’s also profitable and now welcomes digital disruption.
-
Of all the 13 consumer businesses on the block in Citi’s Asia revamp, Taiwan was the most prized. DBS’s successful bid bolsters an already profitable business – and doing so required some hard thinking about geopolitics by the Singapore bank’s board.
-
Record profits and fines, a big loss in Indonesia, Citi’s retail departure and a once-in-a-generation merger: it has been a strange year for Taiwan’s over-crowded banking sector.
-
JPMorgan’s blockchain units have launched a new validation solution called Confirm. It is another small step towards mainstream use of the technology in payments.
-
The chief executive of Taiwan lender E.Sun, Joseph Huang, tells Euromoney that banks are responsible for helping not just customers but the whole of society, as Covid-19 pushes countries into lockdown.
-
Despite being a global leader in IT and semiconductors, Taiwan has long been a digital laggard. The regulator has just issued the island’s first digital banking licences, but is it a simple case of ‘too late’ rather than ‘better late than never’?
-
As part of Euromoney's 50th anniversary coverage, we profile some of the biggest names that we interviewed for our May Asia focus.
-
It is unusual for a Taiwanese bank: owned by foreign institutional investors rather than bankrolled by a tycoon or controlled by the state, it’s also on a roll, investing heavily in digital and expanding fast around Asia… but can it last?
-
President Tsai’s flagship foreign policy aims to redirect bank lending and investment away from China and towards southeast Asia. Taiwan has tried to diversify twice before and failed – will it work the third time?
-
A falling number of corporates are choosing to list on the Taiwan Stock Exchange. Given the dire after-market performance of Aslan Pharmaceuticals, it is not hard to see why.
-
Asian banks are increasingly proving themselves to be much more than just volume-hungry lenders.